This is a Japan news story, published by MSN, that relates primarily to Kyoto University Hospital news.
For more Japan news, you can click here:
more Japan newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from MSN, you can click here:
more news from MSNOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
tooth growth. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest congenital tooth deficiency news, groundbreaking tooth news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
tooth regenerationindy100
•
69% Informative
First -of-its-kind drug deactivates the uterine sensitization-associated gene-1 (USAG-1) protein.
Drug prompts bone morphogenetic protein ( BMP ) signalling and encourages the growth of new bone and teeth.
Human trials to start in September 2024 at Kyoto University Hospital in Japan .
If proven successful, the drug could become widely available as soon as 2030 .
VR Score
58
Informative language
53
Neutral language
8
Article tone
informal
Language
English
Language complexity
49
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
2
Source diversity
2
Affiliate links
no affiliate links